Meanwhile, amplifying VEGFC with adenoviral vectors promotes therapeutic lymphangiogenesis, which accelerates the regression of cardiac inflammation after MI, reduces the level of left ventricular T cell and pro-inflammatory macrophage infiltration, delays scar remodeling, and reduces cardiac dysfunction after MI [157]. The gene discussed is VEGFC; the disease is myocardial infarction.